- Home
- EVOK vs ONCO Comparison
EVOK vs ONCO Comparison
Compare EVOK & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVOK
- ONCO
- Stock Information
- Founded
- EVOK 2007
- ONCO 2018
- Country
- EVOK United States
- ONCO United States
- Employees
- EVOK N/A
- ONCO N/A
- Industry
- EVOK Biotechnology: Pharmaceutical Preparations
- ONCO Biotechnology: Pharmaceutical Preparations
- Sector
- EVOK Health Care
- ONCO Health Care
- Exchange
- EVOK Nasdaq
- ONCO Nasdaq
- Market Cap
- EVOK 7.1M
- ONCO 5.8M
- IPO Year
- EVOK 2013
- ONCO 2022
- Fundamental
- Price
- EVOK $5.07
- ONCO $0.40
- Analyst Decision
- EVOK
- ONCO
- Analyst Count
- EVOK 0
- ONCO 0
- Target Price
- EVOK N/A
- ONCO N/A
- AVG Volume (30 Days)
- EVOK 8.5K
- ONCO 9.9M
- Earning Date
- EVOK 03-13-2025
- ONCO 04-10-2025
- Dividend Yield
- EVOK N/A
- ONCO N/A
- EPS Growth
- EVOK N/A
- ONCO N/A
- EPS
- EVOK N/A
- ONCO N/A
- Revenue
- EVOK $8,617,036.00
- ONCO $1,870,605.00
- Revenue This Year
- EVOK $97.35
- ONCO N/A
- Revenue Next Year
- EVOK $99.52
- ONCO N/A
- P/E Ratio
- EVOK N/A
- ONCO N/A
- Revenue Growth
- EVOK 100.35
- ONCO N/A
- 52 Week Low
- EVOK $3.54
- ONCO $0.32
- 52 Week High
- EVOK $12.32
- ONCO $21.40
- Technical
- Relative Strength Index (RSI)
- EVOK 55.10
- ONCO 33.18
- Support Level
- EVOK $4.68
- ONCO $0.58
- Resistance Level
- EVOK $5.40
- ONCO $0.70
- Average True Range (ATR)
- EVOK 0.31
- ONCO 0.06
- MACD
- EVOK 0.03
- ONCO -0.01
- Stochastic Oscillator
- EVOK 57.85
- ONCO 0.00
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.